Vasa Therapeutics

MMP-2/MMP-9 inhibitors for cardiac fibrosis

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
MMP-2/MMP-9Small molecule
Heart Failure

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 November 2026Topline resultVasa Therapeutics VS-041Phase 1c HFpEF trial reports positive topline results
Vasa Therapeutics · Source ↗

Financial reports

No financial reports recorded.